Atrial natriuretic factor: Its (patho)physiological significance in humans  by de Zeeuw, Dick et al.
Kidney International, Vol. 41(1992), pp. 1/15—1133
EDITORIAL REVIEW
Atrial natriuretic factor: Its (patho)physiological significance in
humans
The regulation of sodium and volume homeostasis has been a
topic of research for many decades, Upon the discovery of
many new exciting hormone systems, such as the renin-angio-
tensin-aldosterone system, the prostaglandin cascade, and the
"natriuretic hormone," exhaustive attempts have been made to
obtain insight into the way the human body is so effectively able
to preserve its internal milieu. History has learned, however,
that although these hormones all have their specific place, the
circle explaining the exact mechanism of volume regulation has
not yet been closed. The discovery of the cardiac atrial pep-
tide(s) and their functional properties, elegantly reviewed by
Maack et al in this Journal, is most exciting in this context [I].
Indeed, the logic of a "hormone" that signals from the heart to
the kidney appears so simple that it may indicate that we come
close to the basic understanding of volume homeostasis. A
more detailed understanding of the functions of this peptide
would not only have tremendous physiological and pathophys-
iological significance, but it would also add new therapeutic
approaches to the treatment of the many diseases that are
accompanied by volume overload.
A mountain of scientific publications appeared after the
pioneer work of de Bold et al showing that the cardiac atria
contain a powerful substance capable of reducing systemic
blood pressure and inducing natriuresis [2]. This data offered us
insight into the production and function of atrial peptides.
However, it also brought many areas of conflict. The most
trivial in this respect is the difference in nomenclature, Al-
though the term "atrial natriuretic factor" has been advocated
as the trivial name [3], alternatives such as atrial natriuretic
peptide are still being used. For practical purposes we will refer
to atrial peptides as atrial natriuretic factor, in short ANF. Of
more importance are the various discrepancies in the data
concerning the effects and mechanism(s) of action of ANF. A
list of reported actions is shown in Table 1. Only few of these
effects remain relatively non-controversial such as the hemo-
concentration and the natriuresis following ANF administra-
tion. As far as the other alledged effects are concerned, one may
find data that suggest either no or even opposite effects, for
example regarding changes in blood pressure, in GFR, in renal
blood flow, and in hormone interactions. We feel that a large
proportion of these discrepancies can be explained by a few
basic variations in the used protocol of the different studies, as
listed in Table 2.
The purpose of this review is not to reiterate the numerous
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animal studies which form the backbone of our current under-
standing of the role of ANF and which have been interpreted in
many excellent previous reviews [4—14]. We will mainly focus
on the available human data and make an attempt to relate the
current knowledge on ANF to its significance for human
physiology and pathophysiology, taking into account as much
as possible the above-mentioned factors of bias (Table 2).
Release
Production site
The main production site of ANF is, at least in mammalian
vertebrates, localized in the cardiac atria. Kisch [15] and later
Jamieson and Palade [16] referred to these sites as dense
bodies. Many years passed before these granules were identi-
fied as the main production and storage sites of precursor and
perhaps active ANF both in animals and in humans [17, 181.
Many elegant animal experiments have subsequently confirmed
the presence of ANF in these granules and have shown that the
contents of these stores can be depleted and refueled by
physiological and non-physiological stimuli [19—22]. Although
the heart was thus recognized to be not only a pump but also a
secretory organ for a hormone [23], we should not be trapped
by oversimplifying this concept. For many years the renin-
angiotensin system was believed to be located in a few single
organ systems. This led to rather undifferentiated models of its
(patho)physiological actions. However, with the use of new cell
biology techniques, mRNA for the different components of the
system has been identified in many other tissues. Similarly,
coding genes for ANF or ANF-like products have been found in
other tissues than the cardiac atria, such as the cardiac ventri-
cle, central nervous system, blood vessels, adrenals and diges-
tive tract [13]. The precise function of this extra-atrial ANF, be
it endocrine, paracrine, and/or autocrine sites, has yet to be
established. Clearly the human cardiac atria produce the major
fraction of circulating ANF.
Formation
In human atrial tissue three distinct peptides have been
distinguished: a, /3, and yANF [24, 25]. These are all derived
from the 151 amino acid precursor molecule (prepropeptide),
consisting of a 126 amino acid propeptide (yANF) and an
N-terminal signal polypeptide. From the propeptide, the 28
amino acid aANF is cleaved from the carboxy-terminus, leav-
ing the N-terminal 7ANF fragment. The synthesis of the
antiparallel dimer of aANF called /3ANF is not yet understood.
All these peptides have been identified in human plasma,
however in distinct quantities [26—29]. The most predominant
are aANF and the N-terminal yANF fragment, whereas the
propeptide is found in abundant quantities in the granular atrial
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Table 1. Reported effects of atrial natriuretic factor (ANF)
in humans
1. Systemic effects
— blood pressure fall
— hemoconcentration
2. Hormonal effects
— fall in plasma renin (activity)
— fall in aldosterone, cortisol and rise in testosterone levels
— inhibition of arginine vasopressin secretion and/or effects
— induction of pancreatic juice secretion
— modulation of insulin secretion and/or metabolism
3. Renal effects
— rise in glomerular filtration rate
— fall in effective renal plasma flow
rise in filtration fraction
— rise in renovascular resistance
— rise in urinary volume and electrolytes
4. Central nervous system effects
— modulation of sympathetic activity
— increase in heart rate
— increase in lipolysis
— effects on blood pressure-/volume-regulatory regions in the brain
5. Cardiac effects
— coronary vasodilation
— left ventricular performance
— cardiac output reduction
6. Pulmonary effects
— relaxation of vascular smooth muscle cells
— relaxation of the trachea
Table 2. Factors determining the ANF response
I. Species difference
2. Dose of the administered ANF
3. Duration of the ANF administration (length of observation period)
4. Sodium/volume sLatus of the studied subject
5. Blood pressure of the studied subject
6. Posture of the studied subject
__________
ported with the artificial Jarvik-7 heart, results in an immediate
ANF release [45]. In addition, several other manipulations
including (isotonic or hypertonic) volume expansion [46—48],
changes in posture [49], head-out water immersion [50], an
increase in dietary sodium intake [46, 49] and mineralocorticoid
[51], norepinephrine [52], and angiotensin II [52, 53] adminis-
tration have been advocated to lead to a rise in ANF, whereas
a fall in plasma ANF levels was induced through measures like
furosemide administration [47, 48] and sodium depletion [54].
Since several of these studies show a close correlation between
the degree of change in intravascular volume and the ensuing
ANF secretion, it is tentative to conclude that all these maneu-
vers act via the same trigger mechanism, that is, a change in
atrial wall tension, either directly or via a rise in atrial pressure,
leading to a change in the release of ANF.
Plasma levels
stores and only in very small quantities in human plasma in
some patients [30]. This suggests that the processing of the
propeptide into the aANF and N-terminal fragment occurs just
before, during or just after secretion from the cardiac stores.
As far as the biological activity of the different peptides is
concerned, the propeptide probably only has a delivery role for
aANF, whereas the latter determines the biological responses.
The function of pANF remains uncertain.
Cardiac release triggers
The mechanism that results in a release of ANF from the
cardiac atria appears to be multiple. Teleologically, atrial
pressure or atrial wall stretch as a mechanism of release of ANF
would ideally fit into the concept of a 'third factor" in the
regulation of volume homeostasis. Indeed, many animal studies
have shown that a directly induced increment in atnal pressure
and/or in atrial stretch results in ANF release [31]. However, a
large number of other trigger mechanisms have been proposed
including the baroreceptor system [32], the frequency of atrial
contractions [33], intravascular sodium/volume [34], and adre-
nal and pituitary gland hormones [35, 36]. In human studies,
many authors have established a relation between atrial pres-
sure/diameter and plasma ANF levels in disease states, suggest-
ing that patients with high atrial pressures (or large atrial
diameters) have an increased cardiac ANF release [37—40].
However, these cross sectional studies lack evidence for the
atrial pressure/diameter to be the direct cause of the increased
ANF levels. More convincing in this respect are the studies
showing that cardiac perturbations (such as atrial or ventricular
pacing) result in an increase of right atrial pressure, followed by
an immediate cardiac release of ANF [41—44]. These findings
are supported by the elegant study of Schwab et al showing that
an imposed increment of right atrial pressure in patients sup-
To date no world standard is available as to how to measure
human ANF. It has become clear that, despite the introduction
of an international standard ANF sample [3], various parame-
ters may introduce bias such as the use of a plasma extraction
procedure [26] and the source of the antibody used [55].
Moreover, since antibodies are directed against the C-terminal
sequence one may not be certain whether one is measuring the
biologically active aANF, the precursor molecule, or degrada-
tion products. For this reason, it has been suggested that the
term immunoreactive ANF (1rANF) be used for data derived
from RIA ANF measurements [3]. Normal levels of irANF are
not only hard to define because of the lack of assay standardi-
zation, but also because of the fact that the condition of the
"normal" subject varies within and between studied popula-
tions. Factors like the sodium/volume status [46], systemic
blood pressure [56, 57], posture [49, 58], age [58—61], heart- and
renal function [37, 62], and time of sampling [63—65] do have an
effect on the outcome of the measurement. Thus, it is not
surprising taking into account all the above-mentioned varia-
tions, that we find "normal" values for plasma irANF in
healthy men (younger than 65 years) to range from 10 to 70
pg/mI. In this respect a parallel can be drawn with the broad
range of "normal" values of plasma renin activity. An under-
estimated item concerning the possible bias present in defining
the normal values of plasma irANF is the variation in break-
down of ANF. Obviously, plasma levels depend on release as
well as on plasma clearance. Interestingly, we found that a 1
jig/mm exogenously infused synthetic human sANF in different
supine healthy subjects on a standardized sodium intake results
in considerably different increments of plasma irANF levels
between the individuals (Fig. 1) [66]. Similarly, Gillies et al
found that during a constant infusion of aANF in healthy
volunteers a change in posture induced a varying increment in
irANF levels [67]. The measured change in irANF levels
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Fig. 1. The effect of a two-hour infusion of synthetic human aANF (I
p.glmin) on plasma lerels (PlAN,) in 7 healthy subjects. irANF levels
show a considerable individual variation in response to the same
amount of infused ANF. The induced irANF levels correlated with the
induced rise in fractional sodium excretion (zFEN). (Reproduced by
permission from 1661).
induced either by physiological maneuvers or by exogenous
infusion may thus well be confounded by a change in plasma
irANF clearance. Thus, it appears to be at least speculative to
assess a normal range of plasma irANF considering the above-
mentioned factors that have a direct or indirect impact on the
irANF level itself. Moreover, these attempts to define a "nor-
mal" irANF level lead inevitably to defining categories of
subjects with "abnormal" levels (such as in the case of certain
disease states). In light of the above-mentioned bias, we feel
that interpretations of "static" irANF levels between groups or
laboratories remain extremely hazardous, although sometimes
they are our only tool. In contrast, data on changes of irANF
levels within individuals appear to be more valid.
Clearance
The data on human irANF (pharmaco)kinetics are rather
uniform: the distribution volume appears to be 10 to 17 liters,
plasma half-life 2.5 to 4.5 minutes, and the mean plasma
clearance 1.7 to 3.9 1/mm, possibly depending on the investi-
gated dose [68—70]. It was established that irANF is not, or is
only very slowly broken down by circulating plasma enzymes
[81. Multiple organs effectively extract ANF from the blood: the
liver, kidney and lower limb all extract approximately 20 to 50%
of the irANF influx, whereas the data on lung extraction vary
from negligible to 20% extraction [70—73]. This removal from
the vascular compartment may either occur through receptor
binding and subsequent transfer, or through ANF degradation
by specific or non-specific enzymes located within these tissues
174]. The kidneys appear to be one of the major sites of plasma
extraction, since renal extraction of irANF is 50%and since the
kidneys are the organs with the highest blood flow per gram of
tissue. Indeed, Vierhapper et al calculated the renal clearance
to be approximately 20% of the total metabolic irANF clearance
[70]. This renal clearance appears to occur along at least two
different pathways. First, part of the circulating ANF is filtered,
reaching the proximal tubule, where it is degraded by a specific
enzyme, neutral endopeptidase 24.11 [75—78]. Apparently,
some of the ANF escapes this degradation and is retrieved in
the final urine [79]. The function of this degradation is shown by
Margulies et al, who found that infusion of an inhibitor of this
enzyme enhances the effects of intrarenally infused ANF [80].
The second pathway is formed by receptor binding [81, 821.
These so-called clearance receptors (C-receptors, vide infra)
are capable of binding ANF, followed by a rapid cell internal-
ization of the receptor-ligand, and subsequent lysosomal hy-
drolysis of ANF [82]. The major part of the renal C-receptors
are found in the glomeruli [81, 83]. Which of these two
pathways constitutes the predominant ANF-clearance function
remains to be established. Interestingly, Suzuki et al demon-
600 strated in the rat that non-filtering kidneys still extract a major
portion of infused ANF [81].
In summary, the atrial ANF release in humans appears to be
predominantly regulated by the many factors that influence
atrial wall tension/stretch. The subsequently released ANF is
very rapidly removed from the circulation by different tissues,
of which the kidney appears to be one of the important organs.
Apparently, large variations can be found between individuals
with respect to both ANF release as well as plasma clearance,
which may account (besides lack of assay standardization) for
the wide normal range of irANF in normal individuals.
Receptors
The current knowledge on ANF-receptors is derived from
animal studies, as tools for human receptor studies are limited.
In the following paragraph we will try to briefly summarize
some of the data relevant to this review. For more detailed
information we refer to previous reviews [83—89],
Specific binding sites for ANF are localized in various animal
tissues, particularly those known to be important in the homeo-
stasis of volume and blood pressure such as vascular tissues,
specific brain areas, adrenal glomerulosa cells, and several
renal sites. In the kidney vascular ANF binding has been
demonstrated, both by autoradiographic and immunohisto-
chemical techniques, in the renal artery wall [90, 91], the
glomeruli [90—921 and the descending vasa recta [90, 93, 94].
Data on the presence of ANF receptors at the afferent and
efferent arteriole are conflicting [91, 94]. Tubular ANF receptor
binding sites have been observed in the inner medullary collect-
ing tubule (IMCD) [91, 93]. The other tubular segments seem to
be devoid of ANF receptors, although some of the above-
mentioned studies reported weak binding of '251-ANF at the
proximal tubule. Figueroa et al recently demonstrated ANF
localization in human distal convoluted tubular cells besides
collecting duct cells [95]. Intriguingly, animal studies on the
distribution of ANF binding sites within the kidney show that
the majority of ANF binds at a cortical level, whereas less than
2% is found in the renal papilla. However, the density of these
latter sites is fairly high [81, 83].
Quantitative analysis of ANF binding data and affinity label-
ing and cross linking studies have shown a heterogeneity in
ANF receptors. Recent evidence points to the existence of at
least two independent ANF receptors [96—98]: a protein with an
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apparent molecular mass of 70 Kd and one of 130 Kd. The latter
one is coupled to guanylate cyclase, Upon ANF binding to this
site, cGMP formation is also stimulated in humans [99], eliciting
a cascade of cellular responses leading to vasodilation, as well
as, albeit preliminary evidence, to inhibition of renin secretion
and sodium transport in kidney cells [86, 88]. Moreover, the
different biological effects have been correlated with rises in
plasma and/or urinary cGMP levels. For this reason this 130 Kd
protein has been labeled as the biologically active receptor.
B-receptor. Whether other signal transductions beside cGMP,
such as cAMP, are involved with (B-) receptor function remains
to be elucidated 1100, 101]. The 70 Kd receptor appears not to
be coupled to guanylate cyclase, and does not appear to evoke
a biological response. Upon binding of ANF to this receptor,
the complex is internalized, the receptor recycles, and ANF
undergoes lysosomal hydrolysis [82]. This biologically silent
receptor is therefore called the clearance receptor, C-receptor.
Very recently a third receptor type coupled to guanylate
cyclase was defined. This receptor is almost identical to the 130
Kd receptor, but is mainly activated by brain natriuretic peptide
[102]. Its function is as yet unknown.
Interestingly, the distribution of B- and C-receptors over
different tissues is not uniform [103]. Within the kidney Nus-
senzveig et a! demonstrated that Fc-receptors constitute 90% of
the total ANF binding in glomeruli, 30% in mesengial cells, and
50% in the renal papilla [83]. This anatomical heterogeneity
suggests again that each receptor has a specific function.
Important for the understanding of the variation of ANF
effects under specific conditions may well be whether B- and/or
C-receptor numbers can be regulated. There is indeed some
evidence suggesting that high ANF levels may down-regulate
ANF-receptor numbers and cGMP formation [104], Interest-
ingly, in vivo changes in sodium intake appeared to affect
mainly the C-receptor density [105, 106], whereas such an effect
has also been suggested for angiotensin II [107, 108]. Despite
these interesting findings, we should realize that in some studies
these phenomena may have been biased by increasing receptor
occupancy by higher ANF levels, Furthermore, if down-regu-
lation does occur in certain situations, it is important to
differentiate between B- and C-receptors, since down-regula-
tion of the C-receptor results in increased ANF levels which
could in turn enhance the B-receptor mediated response [109].
This differentiation has not been made in most of the in vivo
ANF studies to date.
In summary, at least two types of ANF receptors, a biolog-
ically active B-receptor and a clearance C-receptor, are present
in many tissues involved in the regulation of blood pressure and
volume homeostasis. The ratio of the subtypes of ANF recep-
tors varies between tissues. Whether or not the prevailing
physiological status may modulate the effects of ANF adminis-
tration through (differential) receptor-number regulation of the
ANF receptor subtypes in the various tissues remains to be
elucidated.
Effects of ANF administration
There are many problems when attempting to classify the
vast number of reported effects of ANF because of the apparent
non-uniformity of the current data. Certainly, it is tempting to
simply follow up on the classical first experiments on ANF
infusion in animals and humans which show a fall in systemic
blood pressure, a rise in hematocrit and a clear natriuresis [2,
110—112]. However, the results of later human studies cast
serious doubt as to whether one may assume the ANF function
to range over this specific spectrum of effects. Although natri-
uresis was reported in nearly all studies, blood pressure effects
were highly variable, and hormonal effects were added to the
list of ANF functions. Interestingly, all studies used different
protocols with respect to ANF dose, duration of ANF infusion,
and observation time. Moreover, most of the studies on ANF
were uncontrolled for the preexisting volume/sodium status,
prevailing systemic blood pressure, or posture of the studied
individual, Thus, the study protocol may have influenced the
outcome of a particular study. In the next paragraphs we will
focus on the systemic, hormonal and renal effects of ANF, with
special emphasis on the factors that determine the human
response.
Systemic effects
Pharmacological doses of ANF almost consistently result in
an immediate systemic blood pressure fall in animals. The
hypotensive mechanism involved has been studied extensively.
Although in vitro studies [1] in isolated vessels demonstrated
the vasodilatory capacity of ANF, the role of systemic vasodi-
lation in the hypotensive effect in the intact animal remains
controversial, since total peripheral resistance remains constant
or even increases [113—117]. The hypotensive action appears
rather to be the result of a fall in cardiac output, most likely due
to a reduced filling pressure [115, 116]. It has been suggested
that reduced venous tone and decreased blood volume may
contribute to the reduction in filling pressure. Indeed, ANF has
been demonstrated to induce an extravascular fluid shift, result-
ing in hemoconcentration [118].
In humans, pharmacological doses of ANF also elicit an
acute fall in systemic blood pressure. However, the acute
hypotensive mechanism appears to be different from that in
animals. Bussien et al suggested that vasodilation plays an
important role [119]. Indeed, heart rate almost invariably
acutely rises upon ANF bolus injection or ANF infusion
[110-112, 119, 1201. Furthermore, cutaneous vasodilation oc-
curs upon systemic ANF administration, and forearm resis-
tance falls upon local ANF infusion [121, 122]. Species differ-
ences may explain the different vascular response between
animals and humans [123]. On the other hand, the heterogeneity
in the response of the different vascular beds studied in animals
and humans may play a role [1]. Similar to the animal data,
human studies show the rapid hemoconcentrative effect of ANF
[12, 120, 124], as well as a fall in cardiac output [125]. However,
no effects on cardiac output have been reported [126]. Although
it seems appropriate to assume that a combination of vasodila-
tion and/or extravascular fluid shift, and/or a fall in cardiac
output underly the ANF-induced acute fall in systemic blood
pressure in humans, the presence and relative contribution of
each of these factors has yet to be established. This is particu-
larly important since relations between these factors and the
blood pressure response are not always present [120, 124].
Interpretation of the mechanism(s) that play a role in the
hypotensive response to ANF, or even the presence of a
systemic hemodynamic response, are confounded by the fact
that this response depends on certain protocol conditions, such
as the ANF dose, the duration of the ANF infusion, and
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possibly the sodium/volume status of the studied subject.
Obviously, the dose of the administered ANF influences the
type and magnitude of the response [127—1291. The early
high-dose human experiments of Richards et al and Weder et al
showed that 100 sg ANF as a bolus injection or 2 to 30 (!)
tg/min as a sustained infusion caused a dramatic fall in sys-
temic blood pressure similar to that observed in animal exper-
iments [110, 1291. However, many later human studies have
employed much lower doses, even as low as 0.16 g/min,
showing no hypotensive effect at all or even a small pressor
effect [127, 130—136]. Richards et al elegantly showed that
inhibition of the enzyme that degrades endogenous ANF,
leading to a very small but significant increase of plasma irANF
levels, does not have any effect on systemic blood pressure
[137]. Thus, it seems valid to state that only high doses ofANF
(leading to supraphysiological irANF plasma levels) result in an
immediate fall of systemic blood pressure. Interpretation of the
data on the effect of low-dose ANF on blood pressure is
complicated by the differences between studies as far as the
duration of the ANF infusion. Whereas many studies have
shown that low-dose infusions (leading only to high range
physiological irANF plasma levels) have no effect on blood
pressure when given over a period of maximally six hours, we
found in a five-day infusion study that similar low-dose ANF
results in a distinct blood pressure fall only after 12 hours from
the start of infusion (Fig. 2) [138]. Similar observations have
been made showing a delayed hypotensive effect after pro-
longed ANF infusion (or endogenous ANF breakdown inhibi-
tion) both in animals [139—143] and in humans [144]. Appar-
ently, the duration of infusion does play a role in the outcome of
a blood pressure response in such low-dose infusion studies.
How may we interpret these findings? At least three mecha-
nisms have been suggested to explain this delayed response:
systemic vasodilation, decreased circulating volume (through
extracellular volume shifts and/or negative sodium balance
caused by the sustained natriuresis), or a combination of both.
Both could well be a result of a direct action of ANF on the
systemic and renal vasculature, and/or an indirect action
through inhibition of the renin-angiotensin-aldosterone system
[139]. The cited long-term infusion studies in humans both show
that an ANF-induced negative sodium balance may play an
important role [138, 144]. Indeed, Figure 2 shows that the fall in
blood pressure is preceded by a sustained natriuresis causing a
negative sodium balance [138]. Garcia et al had suggested a
similar mechanism in an animal study [1411. However, systemic
vasodilation cannot be ruled out as an important determinant of
the blood pressure response. In this context it is important to
note that this delayed blood pressure lowering response was
only found to occur in hypertensive animal models and hyper-
tensive patients, and not in the normotensive controls.
Another complicating factor in unraveling an ANF dose-
response relation is probably the sodium/volume status of the
studied subject. A higher sodium intake will result in enhanced
irANF levels and a lower activity of the renin-angiotensin-
aldosterone system, and both are most likely associated with a
lower response to circulating/exogenous ANF (vide supra). We
indeed observed in humans that the blood pressure response
after low-dose ANF infusion is enhanced in a sodium deplete
state compared to a sodium replete state [127]. Similar obser-
vations were made when analyzing the studies of Gaillard et al
and Cuneo et al [145, 146]. In both studies diastolic blood
pressure tended to fall more during the low sodium diet,
although no statistical significance in the difference was
reached. In contrast, others found no significant difference in
the blood pressure response during different sodium intakes
[120, 129, 147]. However, comparison between these studies
with respect to the possible difference in response on different
sodium intakes remains difficult, since different ANF dose and
infusion protocols were used.
In summary, high ANF doses will elicit a rapid fall in
systemic blood pressure, probably mediated through acute
systemic hemodynamic changes. Lower dose ANF infusions
(or ANF breakdown inhibitors), mimicking physiological
changes in irANF levels, have no immediate effect on systemic
blood pressure. However, prolonged infusion of low-dose ANF
will eventually induce a fall in blood pressure, probably medi-
ated through a combination of factors including the sustained
natriuretic effect of ANF. Because of the non-physiological
irANF plasma levels reached during high-dose studies, we tend
to conclude that ANF has no physiological significance as far as
the short term regulation of systemic blood pressure is con-
cerned.
Hormonal effects
ANF has been found to induce changes in plasma renin
(PRA), aldosterone (PAC), catecholamines, cortisol, arginine
vasopressin (AVP) and dopamine. Again, a wide variety in
responses to ANF infusion has been reported in humans.
During high doses of ANF, PRA and PAC remain unchanged
[110—112] or increased [147], the latter probably reflecting an
activation of the renin-angiotensin-aldosterone system (RAAS)
secondary to a hypotensive action and/or volume depletion
through ANF. Low-dose studies, however, more or less con-
sistently show that PRA and PAC fall upon ANF infusion
[13 1—134, 148]. Interestingly, Richards et al showed in humans
that PRA and PAC also fall after inhibition of the enzyme that
degrades endogenous ANF, which had led to small but signifi-
cant increases in plasma irANF levels [137]. The effect of ANF
on renin and/or aldosterone also appears to be dependent on the
sodium state of the infused subject [146, 147]: a low sodium diet
enhances the suppressive effects of ANF on PRA and/or PAC,
compared to a high sodium diet. This phenomenon suggests that
activation of the RAAS enhances the suppressive responses of
ANF on exponents of this system. Indeed, Richards et al found
that the PRA/PAC suppression, following endopeptidase inhi-
bition, was more pronounced in standing compared to supine
position [137]. Since most of the current (human) studies have
not controlled for sodium intake adequately, it is hard to align
all the data. However, there is ample evidence that ANF has a
(direct) inhibitory effect on exponents of the RAAS. What the
exact mechanism of this suppressive effect of ANF on renin is,
remains uncertain. In vitro animal studies on juxtaglomerular
cells are conflicting, reporting stimulation [149] as well as
inhibition [150, 151]. As far as aldosterone is concerned, in vitro
studies generally agree on ANF causing an inhibition of aldo-
sterone release from adrenal cortical cells. This appears to be
the result of an inhibition of angiotensin II stimulated aldoste-
rone secretion [152—154].
As far as effects of ANF on norepinephrine, most human
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studies agree on a rise of this hormone paralleling the ANF-
induced rise in heart rate [112, 134, 146, 1471. This action
appears dose related [1341 and is enhanced by sodium depletion
[146]. Some low-dose infusion studies, however, fail to demon-
strate any effect on norepinephrine [131—133]. The most likely
explanation for this discrepancy is that the high-dose ANF
studies usually evoke a fall in systemic blood pressure resulting
in a probably baroreflex-mediated activation of the sympathetic
nervous system. Similarly, low-dose ANF infusions have no
Fig. 2. The effect qf a continuous five-day
infusion of 0.2 p.g/min synthetic human aANF
in 6 patients with essential hypertension. The
top panel shows the rise of plasma 1rANF
levels (mean SEM) before, during, and after
infusion. The middle panel shows the
significant fall in both systolic and diastolic
blood pressure (mean SEM) starting after
hours of infusion. The bottom panel
shows the negative cumulative sodium
balance. (Reproduced by permission from
[1381).
significant effect on cortisol and/or dopamine production. Both
high- and low-dose ANF infusions in salt replete and deplete
conditions also appear not to affect AVP plasma levels [128,
146], although a role for ANF in modulating the renal action of
AVP may exist [155].
Thus, as far as the effects of ANF on hormonal production in
humans is concerned, low dose ANF only has been found to
inhibit the renin-angiotensin-aldosterone system, possibly me-
diated through direct action(s) of ANF. For other hormonal
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systems the effect is at least not detected, or if present, is
possibly mediated through indirect activations ensuing from
ANF actions on blood pressure and/or volume related param-
eters.
Renal effects
The namegiving of ANF leaves no doubt as to what was
initially thought to be the prime function of this peptide. Indeed,
at first the renal effect seemed to be rather straightforward:
"natriuretic." However, the picture has become much more
complex, since various investigators have brought forward
multiple renal ANF actions: increase of different urinary elec-
trolytes, renal hemodynamic changes, and changes in hormones
(vide supra) that affect renal functions. Whether one should
look at these different areas as part of an integrated renal ANF
response is hard to discern. Not only are we confronted with
considerable discrepancies and variations in the data reported
within each separate area, the interpretations are also limited
because of the intricate interplay between the different areas.
We will therefore first discuss the effects of ANF on electrolyte
excretion and renal hemodynamics separately, and will try to
combine the observations by identifying the possible mecha-
nism of these renal ANF actions.
Electrolyte excretion
As far as the data on renal excretory function are concerned,
there is no doubt that ANF causes an increase in urinary
volume and sodium output. In addition, many authors have
reported changes in other urinary electrolytes: urinary chloride,
potassium, calcium, phosphate, magnesium, as well as a rise in
urinary protein (albumin) and free water excretion; urinary
osmolality is frequently reported to fall [110—112, 127—135, 138,
145, 146, 156, 157]. However, the presence and/or magnitude of
the response of each parameter varies considerably from study
to study. As discussed in the paragraph on systemic effects, the
renal response also appears to be determined by factors like
ANF dose, infusion time, and the conditions determining the
sensitivity to exogenous ANF infusion.
As far as the natriuretic response is concerned, Cody et al
showed that one hour infusions of doses varying from 0.6 to 6
j.g/min ANF in healthy volunteers resulted in increasing plasma
irANF levels and increasing sodium output up to three times the
control value [1571. However, the variations within one dose
group were considerable. Weder et al tested the effect of
moderate to extremely high dose of ANF (from 2 to 30 sg/min)
in essential hypertensives and found a clear relation between
dose and natriuretic response [129]. Although there apparently
is a clear dose natriuretic-response relation, the threshold
varies considerably. Whereas Cody et al determined the thresh-
old natriuretic response to be at 1.8 g/min ANF dose, we and
others observed distinct natriuretic responses at lower doses
[128, 130—133, 138, 148]. Richards et a! demonstrated that even
small rises in endogenous irANF (from 10 to 15 pmol/liter)
result in a rise in urinary cGMP excretion as well as a clear
natriuresis [137]. Factors other than the infusion dose itself may
determine the characteristics of the relation. First of all, the
level of plasma irANF reached by the constant infusion (or
bolus injection) must be taken into consideration. Despite a
standardized infusion protocol, we observed marked individual
differences in the levels of irANF induced by the same amount
Fig. 3. The effects of low-dose synthetic human aANF infusion (0.16
g/min) in 6 norma! subjects. The top panel shows the urinary sodium
excretion before, during, and after placebo (LI) and ANF (U) infusion.
The bottom panel shows the course of urinary cGMP. For both
variables excretion rates were significantly greater during ANF than
during placebo infusions (P < 0.001). (Reproduced by permission from
[132]).
of infused ANF [66]. Interestingly, a close correlation was
found between the irANF level and the degree of natriuresis
(Fig. I). Thus, similar amounts of ANF infused in different
individuals need not evoke a similar natriuretic response.
Another important factor that may explain the observed differ-
ences in the ANF natriuretic response and/or threshold is to be
found in the duration of the ANF infusion time period. The first
low-dose (0.6 g/min) infusion study by Cody et a! measured no
natriuretic effect during a one hour ANF infusion time [157].
However, in (approximately similar) low-dose studies of Biollaz
et al, Anderson et at, and Solomon et al changes in natriuresis
plateaued after infusion hours and reached only values
significantly different from placebo in the second or third hour
of infusion [128, 130, 133]. In contrast however, Richards et al
found natriuretic effects already in the first 30 minutes using a
dose as low as 0.16 sg/min, where this effect appears to be
maximal already in the second half hour of infusion and only
slightly falls during the following periods of the three infusion
hours [132] (Fig. 3). Interestingly, in this study cGMP levels
reached maximum (compared to placebo) in the third infusion
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hour. Thus, in determining an accurate ANF natriuretic thresh-
old or sensitivity one may have to take into account the infusion
duration or at least the time needed for the effect to plateau.
Moreover, the natriuretic response varies with the preexisting
volume/sodium balance and the preexisting systemic blood
pressure level. Several studies have shown that both bolus and
constant infusion of similar amounts of ANF in the same
subject in balance on a low and high sodium intake results in a
quantitatively lower natriuresis during the period with the low
sodium diet [120, 145, 1461. However, the relative rise in
ANF-induced sodium excretion is much higher during the low
sodium intake compared to the high sodium intake. Whereas
some of the authors interpret their data to reflect a reduced
natriuretic sensitivity to ANF during the low sodium intake,
one could also argue that this represents an increased sensitiv-
ity of the natriuretic response to ANF, parallel with the
enhanced sensitivity of the RAAS and blood pressure response
to ANF during sodium depletion, Interestingly, Clinkingbeard,
Sessions and Shenkar only observed a significant natriuretic
effect of a low-dose ANF infusion during a low dietary sodium
intake, not on a high sodium intake [136]. Maybe even more
important, the prevailing systemic blood pressure plays a role in
determining the natriuretic response. Richards et al showed that
a lower preexisting blood pressure level attenuated the natri-
uretic response in healthy subjects and hypertensive subjects
[1581. Moreover, one also has to take into account what effects
the infused ANF has on the individual systemic blood pressure,
If it lowers blood pressure then antinatriuretic mechanisms may
be triggered, thus counteracting and attenuating the natriuretic
action observed in that individual 1127]. This becomes even
more important since the blood pressure response to ANF is
also sodium intake dependent (vide supra).
In general, at least three other electrolytes are affected by
ANF infusion: urinary chloride, calcium and magnesium, which
all increase. The latter two are quantitatively much less affected
by ANF compared to sodium. Therefore, it is harder to pick up
a statistical significance. Again, the effects on these electrolytes
appear to be dependent on dose and duration of ANF infusion.
This may explain why studies using low-dose and short infusion
times fail to observe a change in urinary excretion of these
electrolytes, whereas short-term high-dose and long-term low-
dose studies report a significant increase. The same applies to
the ANF-induced rise in free water excretion and the fall in
urinary osmolality. The effects of ANF on phosphate excretion
vary. Although a dose and duration of ANF infusion appear to
play a role, even very small increments of plasma 1rANF may
elicit a small but significant increase in phosphate excretion
[137]. In general, potassium excretion is not affected by ANF
infusion even at higher doses, although again exceptions are
present.
From all the above data it seems safe to conclude that the
main effect of exogenous ANF on renal excretory function
remains its natriuretic and chloriuretic action. A dose response
relation is present. However, since many factors appear to
determine the individual response, the threshold for a natri-
uretic response to exogenously infused ANF remains hard to
define, but it may well be below 0.16 g/min, at which dose
irANF levels are approximately doubled. The natriuretic effect
appears to increase during infusion and may only reach plateau
on an hour time scale. These data and the fact that inhibition of
endogenous ANF breakdown, all leading to very mild eleva-
tions in plasma irANF levels, still result in a clear natriuresis,
underscore the potential physiological role of ANF in sodium
homeostasis. Whether changes in other electrolytes and water
handling are quantitatively relevant remains yet to be deter-
mined. Certainly, they may be of extreme importance in unrav-
eling the mechanism(s) of the natriuretic action of ANF, and as
such they will be discussed in another section (vide infra).
Renal hemodynamics
The profile of the renal hemodynamic changes induced by
ANF infusions in humans is not quite uniform.
As far as GFR is concerned the first human studies demon-
strated a slight but significant rise in EDTA clearance upon
ANF infusion [112]. These data were compatible with the
general concept derived from the first animal studies that ANF
causes a clear GFR rise, However, these first human studies
(like the animal studies) were carried out with high doses of
ANF. Although later studies in anesthetized animals using
much lower doses of ANF still demonstrated a rise in GFR,
many later human studies using lower ANF doses failed to
detect a significant effect on GFR [128, 13 1—135, 1591. It is hard
to explain this discrepancy between animal and human studies.
It could be that apart from (unproven) species differences, the
anesthesia (in animals) plays a role, since anesthesia (and
surgery) could potentiate the ANF effects directly and/or indi-
rectly because of a stimulated RAAS. Furthermore, some
caution is warranted before concluding that GFR is not affected
by ANF, since the different techniques used to measure GFR
do have their inaccuracies, and it may well be that we fail to
detect subtle GFR changes in humans. The mechanism by
which ANF may increase GFR is still debated. Pre-glomerular
vasodilation [160—162] might lead to increased transmission of
systemic blood pressure into the glomenilar capillaries, leading
to increased glomerular pressure. In addition, postglomerular
vasoconstriction has been suggested to occur upon ANF infu-
sion [1, 160, 161, 163]. Both could lead to a rise in GFR.
Alternatively, ANF may induce changes in the capillary per-
meability of the glomerular basement membrane leading to an
increased GFR [164].
With respect to the effect of ANF on renal blood flow, the
first human report mentioned no significant effect of a high ANF
dose on effective renal plasma flow (ERPF) [112]. Later studies,
however, using lower ANF doses showed a significant fall in
ERPF varying from 20 to 30% [128, 131, 133]. Interestingly,
Richards et al as well as Brown and O'Flynn found no effect on
ERPF using even lower doses [132, 135]. Apart from these dose
differences the duration of the ANF infusion also appears to
play a role. Biollaz et al found that low-dose ANF will elicit its
ERPF lowering effect only in the third hour of infusion [128].
This suggests that even low-dose ANF may affect ERPF only
with an increased time lapse. Thus, although high doses of ANF
do not appear to lower ERPF (maybe due to renal autoregula-
tion upon the distinct systemic blood pressure fall), one would
tend to conclude that ANF causes a (time-dependent) fall in
ERPF. This is in agreement with the early animal studies,
showing a fall in renal blood flow [I]. There are some pitfalls in
the technique of measuring renal blood flow in humans. In all
cases either a radioactive or non-radioactive PAH-like tracer is
used to assess ERPF. The use of this tracer in estimating
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Fig. 4. The effect (mean SEM) of a 1 g/min infusion of synthetic
human aANF on renal blood flow (RBF) and renal vascular resistance
(RVR) in 7 healthy volunteers. RBF data are derived from measure-
ments of effective renal plasma flow ('311-hippuran clearance) corrected
for renal extraction of this tracer, and arterial hematocrit. Asterisk(s)
indicate a significant (P < 0.05) difference from control values. (Repro-
duced by permission from [165]).
drug-induced changes in renal blood flow is only valid when
renal PAH extraction is not affected by the drug, and if
hematocrit remains unchanged. ANF certainly induces a rise in
hematocrit [131, 147] and may well lower PAR extraction. We
however, established that hippuran extraction in healthy human
volunteers was not lowered upon ANF infusion but appeared to
rise somewhat [165]. When we calculated renal blood flow by
correcting ERPF for changes in extraction and in hematocrit,
we found that 1 pg/min ANF had a significant lowering effect on
renal blood flow (Fig. 4). Since systemic blood pressure did not
fall in this study, we calculated that total renal vascular resis-
tance increased significantly upon ANF infusion. Thus, the fall
in ERPF as reported by many investigators in humans most
likely reflects a true fall in renal blood flow.
Summarizing the above data on renal hemodynamics, in
humans GFR remains stable or slightly increases at higher ANF
infusion doses, whereas ERPF falls or remains equal depending
on the ANF dose and observation time. These data imply that
filtration fraction (FF) should rise, as is indeed observed by
most investigators. These changes in glomerular hemodynamics
are most likely caused by preglomerular vasodilation and
postglomerular vasoconstriction. Whether "pretreatment" pa-
rameters, such as blood pressure and sodium status, which may
influence vasomotor tone of both vessels, determine the hemo-
dynamic response to ANF remains to be clarified.
Mechanism of natriuretic action
Reviews of the data of animal experiments have brought
forward three different hypotheses to explain the natriuretic
effect of ANF: 1) alterations in renal hemodynamics, 2) alter-
ations in tubular sodium reabsorption, 3) renal medullary wash-
out. It is intriguing to notice that one may find extreme
standpoints between the advocates of the different mechanisms.
Apparently, experimental conditions and/or species differences
determine the response to ANF at different renal levels. More-
over, as has been demonstrated in the above paragraphs, ANF
doses and infusion time may also explain many discrepancies.
To evaluate the mechanisms in play for the human situation, we
are bound to address the kidney as a complex integrated black
box, with its obvious limitations in dissociating the different
levels at which renal sodium handling is influenced. Although
this has obvious disadvantages, we would like to stress that
even data from animal experiments on isolated tissues, which
form the foundation of many novel concepts, may confuse us as
to the actual in vivo ANF actions.
As far as renal hemodynamic effects are concerned to explain
ANF induced natriuresis, several mechanisms have been pro-
posed. Firstly, the rise in GFR increases the filtered sodium
load [1631. Secondly, changes in peritubular hemodynamics
may result in decreased proximal tubular sodium reabsorption
[1661. Lastly, redistribution of blood flow within the kidney may
lead to increased natriuresis [1, 167]. Whatever the mechanism,
the natriuretic effects of ANF have been clearly dissociated
from the renal hemodynamic effects in humans, since the
absence of "detectable" renal hemodynamic effects one does
observe natriuresis [112, 128, 131, 132, 159, 168]. This has led
many investigators to conclude that, although renal hemody-
namic effects may indeed enhance ANF-induced natriuresis,
under physiological conditions "direct" tubular effects are of
prime importance. In our opinion, such a general conclusion,
denying a role for renal hemodynamic effects of ANF, is still
rather premature. It should be stressed that the detection of
changes in GFR and ERPF in humans is limited with the current
techniques. An important study in this respect is reported by
Mejia et al, demonstrating that small (such as 5%) changes in
GFR, which certainly may escape detection, can produce
significant alterations in sodium excretion, independent of
changes in tubular sodium handling [169]. The fact that ANF is
reported to induce a preglomerular vasodilation both in animal
and in humans would favor a hemodynamic role for the natri-
uresis. It is harder to reconcile the observation of an ANF-
induced postglomerular vasoconstriction with a hemodynami-
cally mediated natriuresis, since the first would lead to a rise in
peritubular oncotic pressure and thus to antinatriuresis. On the
other hand Mendez et a! suggested that ANF had an opposite
effect on peritubular oncotic pressure [166]. Clearly, this needs
further studies. Furthermore, we can also not exclude that,
although renal blood flow (ERPF) may fall or remain unchanged
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in humans, redistribution of blood flow and thus increased flow
to medullary nephron populations still occurs.
As far as tubular effects are concerned, mainly two different
sites have been investigated in humans: an effect of ANF on
proximal sodium reabsorption and an effect of ANF on distal
sodium reabsorption. Evidence has been built up suggesting
that ANF acts on proximal sodium handling in humans. A
decrease in proximal sodium reabsorption is suggested by the
fact that many human studies, even those inducing small
increments in plasma irANF levels, show the natriuresis to be
accompanied by significant increases in either urinary phos-
phate and/or fractional lithium clearance, both being markers
for proximal solute handling [135, 137, 160, 168, 170—172]. In
addition, free water excretion also increases upon ANF infu-
sion [66, 112, 134, 168, 1711, which is compatible with an effect
of ANF on a tubule segment proximal to the diluting segment
[168]. We demonstrated that this rise in free water excretion
correlates with the rise in fractional sodium excretion [661. All
these factors make the suggestion of a proximal natriuretic
effect of ANF rather strong. Most likely, this effect is indirect
and mediated via an effect of ANF on the RAAS. Not only are
ANF receptors not found in the proximal tubule of animals
(vide supra), there also was no direct ANF effect demonstrable
in this isolated tubule segment [173]. ANF has been shown to
inhibit the RAAS (vide supra), and since angiotensin H at
physiological concentration promotes sodium reabsorption in
the proximal tubular, an inhibiting effect of ANF could well
explain the proximal tubular natriuretic response [164]. Indeed,
studies in humans have shown that the ANF-induced natriure-
sis could be attenuated by inhibition of Ang H formation [174].
Most investigators agree that this proximal effect cannot fully
explain the natriuretic properties of ANF. Distal tubular effects
of ANF are suggested by the rise in the urinary excretion of
calcium and magnesium, and the absence of a kaliuretic effect
(vide supra). Indeed, animal studies showed that ANF inhibits
sodium reabsorption in the collecting ducts, probably the
IMCD. Without this effect the increased distal delivery would
cause less natriuresis [175—177]. In humans, Biollaz et al
calculated that the distal tubule is unable to adequately com-
pensate for the increased sodium load from the proximal tubule
[168]. Moreover, we have demonstrated that ANF induces a
decrease in free water reabsorption in a state of maximal
urinary concentration, and that the fall in free water reabsorp-
tion correlates with fractional sodium excretion [66], suggesting
a distal tubular effect of ANF. Rabelink et al showed that
besides the IMCD, earlier aldosterone-sensitive segments may
also play a role [172]. All these factors, together with the
presence of ANF receptors on distal nephron sites (vide supra),
suggest that distal tubular sites (presumably the IMCD) play an
additive role in the ANF-induced natriuresis. Whether or not
intermediate segments such as the loop of Henle play a role in
humans, remains uncertain.
As far as renal medullary washout and its role in ANF-
induced natriuresjs is concerned, it is clear that this cannot be
looked upon as a separate entity, but more likely as a conse-
quence of the hemodynamic and/or tubular ANF effects. Nev-
ertheless, it may certainly contribute to the ANF-induced
natriuresis [1, 164]. Animal experiments have elegantly shown
the loss of a medullary solute gradient after ANF infusion [178].
Moreover, almost all human studies have demonstrated a
marked fall in urinary osmolality (vide supra), which could
certainly be in line with a medullary washout. Which parame-
ters could evoke a loss of the medullary solute gradient? First of
all, an increased blood flow to the medullary nephrons (despite
the fall in total renal blood flow) could lead to washout. Indeed,
animal experiments have shown such an ANF effect lii, 164,
1671. In addition, the increase in tubular flow via an increased
GFR and reduced proximal sodium/water reabsorption, and the
reduced sodium reabsorption in distal nephrons, all favor a loss
of the medullary solute gradient.
Thus, the mechanism(s) of the ANF-induced natriuresis in
humans appears to be multifactorial: a (small) rise in GFR
and/or a reduction in proximal tubular sodium reabsorption
(probably Ang II mediated) leads to an increased distal solute
delivery, whereas more distally located tubular segments (most
likely the IMCD) add to this effect by not reabsorbing this
excess solute. Medullary washout contributes to the natriuresis
either as a result of the mentioned natriuretic factors or as an
ANF-induced phenomenon on its own.
Pathophysiological role
The vasoclilatory and natriuretic properties of ANF, as dis-
cussed above, obviously are of interest with regard to patho-
physiological disorders associated with vasoconstriction and/or
sodium retention. Thus, the (genetically determined) vasocon-
striction and (subtle) renal sodium retention of essential hyper-
tension has intrigued many investigators having them question
whether there is a deficiency in the release of ANF or whether
there is a diminished vascular and/or renal target-responsive-
ness to ANF. Similar questions have been raised with regard to
the pathophysiological role of ANF in disorders with avid
sodium retention and edema formation such as congestive heart
failure, liver cirrhosis, and the nephrotic syndrome.
Essential hypertension
Plasma irANF levels in adult patients with established essen-
tial hypertension (EH) show a broad range in almost all studies.
Mean irANF levels are reported to be similar, higher, or even
lower in EH compared to normotensives [179—182]. An expla-
nation for this phenomenon may be found in the heterogeneity
of the EH population. Well known is the marked difference in
PRA levels between patients with EH. Since, irANF plasma
levels are reported to inversely correlate with PRA [57, 61,
1791, one might argue that this explains the broad irANF level
spectrum. Moreover, high irANF levels are often found when
the study group consists of severe hypertensive patients with
possible end-organ damage [57, 182]. Thus, irANF levels may
be secondary to the higher blood pressure (vide infra), to the
incipient cardiac and renal failure or left ventricular hypertro-
phy [1821. Although these factors may explain the large varia-
tion in irANF levels, the question remains whether the direct
comparison with "normal" levels is valid? Interestingly, nor-
mal levels of irANF in patients with mild EH have been argued
to indicate a relative deficiency of ANF release. This hypothe-
sis is based on the fact that both the higher blood pressure and
the increased central blood volume in EH compared to control
should have enhanced the ANF release [57]. In favor of such a
possible deficiency of ANF release are recent findings that
off-spring of hypertensive parents show an attenuated ANF
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release upon a high sodium intake [183, 184]. Obviously, more
direct evidence of an altered relationship in EH between
IrANF, PRA, and sodium intake ("irANF-PRA-sodium-profil-
ing"), as well as between atrial pressures, central blood volume
and ANF release, is needed to clarify this issue.
Studies on ANF responsiveness in EH have focused on a
possibly diminished response as far as blood pressure and
natriuresis are concerned. However, several studies using high
as well as low doses of ANF have reported both an attenuated
and an enhanced blood pressure-lowering response in EH
compared to normotensives [144, 158, 185—187]. Similar de-
creases in blood pressure also have been reported 1188]. Cer-
tainly, differences in the doses of ANF, duration of observation
and sodium intake may underly these discrepancies. As far as
the natriuretic response is concerned, both short-term, long-
term and low-, high-doses of ANF are found to cause an equal
or enhanced natnuresis in EH as compared to normotensives
[144, 158, 185—187, 189]. However, the comparison with normal
volunteers should take into account differences in initial condi-
tions such as blood pressure, plasma irANF level and PRA. All
these factors have been suggested to influence the ANF-
induced natriuretic response. A similar natriuretic response
comparing normotensives and hypertensives only differing in
either a higher blood pressure, a lower irANF level or higher
PRA levels, may suggest a relatively attenuated renal sensitiv-
ity to ANF. On the other hand, higher irANF and/or lower PRA
levels in hypertensives may suggest an enhanced renal respon-
siveness. In addition, the natriuretic response may also be
influenced by the degree of ANF-induced blood pressure fall,
since the latter would result in an anti-natriuretic effect.
In summary, irANF levels in EH vary over a wide "physio-
logical" range, and can be interpreted to reject as well as
support the hypothesis of a deficiency of ANF release in EH.
Similarly, data on blood pressure response as well as natriuretic
response to ANF may be interpreted to reflect a normal,
attenuated, or even enhanced response. The greatest challenge
in clarifying the role of ANF in EH to date therefore is to define
the importance of the differences in baseline sodium intake,
blood pressure, PRA and irANF levels as far as these determine
the response to exogenous ANF.
Edematous disorders
In patients with congestive heart failure (CHF) plasma 1rANF
levels are invariably found to be elevated. These elevated
irANF levels increase with the stage of the disease and corre-
late with right and/or left atrial pressures [37, 190, 191]. There-
fore, plasma irANF levels may be of good diagnostic value in
evaluating the hemodynamic status and may have prognostic
significance in CHF [190]. In patients with liver cirrhosis
plasma 1rANF levels are reported to be normal [192—195] or
slightly elevated [196]. Henriksen et al observed normal irANF
levels despite a significantly reduced central blood volume
[195]. The ANF release following head-out-water-immersion
was found to be exaggerated [192], comparable [197], as well as
blunted [1931 in these patients compared to control subjects.
The reason for this variability is unknown, but may be related to
the heterogeneity in etiology, the stage of the cirrhosis, or
diuretic use [194]. Also the amount of sodium intake may be
important. Epstein et al for instance studied the effect of
head-out-water-immersion on ANF release during a 10 mmol
sodium intake [192]. One may expect irANF levels then to be
low and ANF storage sites to be full. This may explain why they
found an exaggerated response, whereas Gerbes et al, who used
a 150 mmol sodium intake, observed a blunted response [193].
In patients with the nephrotic syndrome, data on irANF levels
are conflicting, and normal as well as two times higher or lower
values are reported [198—200]. During acute volume expansion
irANF is released into the circulation in both nephrotic subjects
and in patients with renal failure [200, 201], at least as much as
in normal controls. Thus, evidence for a deficient ANF synthe-
sis or release in these edematous disorders is virtually absent.
As far as the effects of ANF infusion, CHF patients show a
decrease in systemic vascular resistance and an increase in
cardiac output and sodium excretion. Effects of high-dose ANF
infusions in CHF for 30 to 240 minutes showed that ANF can
decrease pulmonary capillary wedge pressure, and systemic
(and pulmonary) arterial pressure, whereas it increased cardiac
index [157, 202—206]. These cardiovascular effects appear to be
at least as high in CHF as in normal controls. In contrast, the
natriuretic effect of these doses of ANF appears to be blunted.
However, lower doses of ANF for up to four hours have been
reported to increase sodium excretion without significant ef-
fects on cardiovascular parameters [207]. Thus, in CHF a renal
hyposensitivity to ANF may exist in the presence of high
irANF levels. It may also be secondary to a low renal perfusion
pressure and/or the activated state of sodium retaining systems.
ANF infusion may have no natriuretic effect in this latter state,
since it may not overcome the prevailing sodium retentive
mechanisms at the proximal tubular level. The action of ANF
on the IMCD may consequently be without effect, and thus no
natriuresis occurs. Alternatively, the high doses of ANF may
have elicited systemic effects which in turn attenuated the
natriuretic actions of ANF.
In patients with liver cirrhosis, the hypotensive action of
exogenous ANF appears to be marked, whereas the natriuretic
effect of ANF appears to be minimal [208, 209], compared to
controls [196]. In cirrhosis high levels of endogenous 1rANF, in
contrast to CHF, cannot he held responsible. Some studies
point to the importance of the high initial levels of PRA or PAC
and the incomplete suppression of these parameters [2101.
Using head-out water immersion experiments, Epstein et al
have shown that the elicited increase in irANF levels dissoci-
ates from the rise in sodium excretion [192], distinct from
normal controls. During identical experiments Skorecki et a!
were able to distinguish renal responders versus non-respond-
ers [197]. In these groups baseline as well as immersion-induced
rises in plasma irANF and cGMP were comparable, indicating
that in both groups ANF release and coupling to its cGMP-
linked receptors are functioning. Both groups, however, dif-
fered in their PRA and PAC levels, which were
higher in the non-responders. These data are similar to those of
Gerbes et al, who furthermore showed that ANF to PAC ratio's
correlated closely to basal and stimulated natriuresis [1931.
Interestingly, urinary potassium excretion increased progres-
sively and markedly in cirrhotic subjects, in contrast to normal
subjects [192, 197, 210]. Thus, in some patients with cirrhosis of
the liver a distal tubular resistance to ANF may exist, and
elevated PRA or PAC levels may serve as mediator or as
marker to such a relative renal hyposensitivity to ANF in these
patients.
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Administration of exogenous ANF to patients with the ne-
phrotic syndrome showed that blood pressure, hematocrit, and
renal hemodynamic and natriuretic effects were comparable to
those in normal controls [199, 211]. The subjects enrolled in
these studies were with or without edema, but none had
extremely avid sodium retention. Peterson et at investigated the
effects of head-out water immersion in patients with the ne-
phrotic syndrome with avid sodium retention, and observed a
blunted natriuretic response and suggested that this could be
due to a relative hyporesponsiveness of the distal tubule to
ANF [200]. However, unlike patients with cirrhosis of the liver,
a natriuretic response was not absent. Interestingly, several
studies indicated that exogenous ANF, already at doses that
induce minor increments in plasma irANF cause an increase in
proteinuria in patients with the nephrotic syndrome [198], an
effect also found in normal and hypertensive subjects [156. 2121.
These findings provide evidence for some interesting feedback
mechanisms: sodium retention with associated hypervolemia
will induce ANF release, which in turn may aggravate or
contribute to the development of proteinuria with an associated
tendency to hypovolemia. This may then lead to, or enhance
(further) sodium retention by increasing sodium retaining fac-
tors and by decreasing ANF release. Finally, a diminished
responsiveness to ANF (during avid sodium retention?) may be
a further complicating factor. Administration of exogenous
ANF to patients with chronic renal failure yielded conflicting
data. Whereas Suda et al found a 2.5-fold increase in urinary
sodium excretion, despite a marked fall in blood pressure
during low-dose ANF infusion, Burnier et at did not find any
effect using the same dose [213, 2141. The reason for this
discrepancy as yet is unclear.
In summary, ANF synthesis and/or release does not appear
to be deficient in congestive heart failure, liver cirrhosis, the
nephrotic syndrome, or chronic renal failure [215]. However,
the endogenous ANF system obviously is not capable of
preventing the vasoconstriction and sodium retention in these
edematous disorders. Nevertheless, ANF still may have a
counterregulatory, albeit weak, role against the activated vas-
oconstrictory and sodium retaining systems in these disorders
such as the RAAS, the sympathetic nervous system and vaso-
pressin. Finally, a negative role for ANF in the formation of
edema deserves further attention.
Physiological role
Despite the vast current knowledge concerning the effects of
ANF, the fundamental function of this peptide is still unknown.
Although two main potential functions have been brought
forward, that is, the regulation of (blood) pressure and the
regulation of volume homeostasis, these areas are still under
heavy debate in the recent literature. Vasan, Seshadri and
Narula state that ANF is just a "vestigial non-functional agent"
[2161. Similarly Goetz concludes that ANF may be of impor-
tance in physiological pressure regulation, but that it has no
physiological significance in the regulation of our daily sodium
homeostasis [217]. In contrast, Richards and Crozier find the
data strongly in support of a fundamental role for ANF in
pressure and volume homeostasis in humans [218]. Similarly,
Blame argues that ANF is a necessary but not sufficient
condition to induce natriuresis [219]. In our opinion, most of
these differences in standpoints are due to the different routes of
approach in defining the physiological significance of ANF. At
the risk of designing a new false route we will try to come to the
conclusion that ANF is not vestigial but an important regulatory
hormone at least in the area of sodium/volume homeostasis.
Clearly, to define whether or not ANF has a regulatory role
one needs to define what the supposed hormone has to regulate.
It is obvious from this monograph that in our opinion only the
lowest dose studies may serve to identify the candidate target
tissue(s), since high-dose studies result in "unphysiological"
plasma irANF levels. We argue that this leaves only the renal
electrolyte excretion and the RAAS as parameters affected by
short-term ANF infusions leading to physiological elevations of
plasma irANF. Whether or not extravascular fluid shifts occur
at these doses is to our knowledge not clearly established.
Probably the best example of a study showing these low-dose
ANF effects is that of Richards et at [132]. In this study ANF
infusion only doubled irANF levels which coincided with an
increase in sodium excretion compared to placebo infusion
(Fig. 3). Whether or riot endogenous irANF levels regulate
sodium homeostasis on a daily basis is not proven by such
experiments. However, Richards et al also demonstrated that
small increases in endogenous plasma irANF levels, induced by
endopeptidase inhibition, result in a natriuresis [1371. Further-
more, Bell et al, studying diurnal rhythms of irANF, cGMP,
PRA and PAC, found that diurnal changes in sodium excretion
could be at least partially explained by changes in endogenous
irANF levels [65]. In this respect our study on the diurnal
sodium rhythm may be of importance [2201. We studied the
effects of a continuous infusion of 0.2 tg ANF/min during five
days in patients with essential hypertension, thereby leveling
off any possible daily variations in endogenous ANF release.
This ANF infusion did not only induce a negative sodium
balance, but also affected the diurnal sodium rhythm by shifting
the peak time. This latter phenomenon remained in effect over
the total five day infusion period (disappearing during recov-
ery), despite the fact that sodium balance was again reached
after two infusion days, Interestingly, no change in the diurnal
levels of PRA was found in this study. Thus, endogenous
irANF variations may be present and determine (part of) the
diurnal rhythm characteristics of sodium excretion. However,
to further establish such a physiological significance of ANF in
sodium homeostasis we need to confirm that the endogenous
ANF release is evoked by changes in the intricate balance
between daily sodium input and output. Indeed, infusion of
saline results in a rise of irANF. However, studies on oral
intake of food containing high and low amounts of sodium fail to
observe a postprandial increase in plasma irANF [217]. This led
Goetz to conclude that ANF is not involved in sodium/volume
homeostasis [217]. However, this conclusion is mainly based
upon measurements of irANF plasma levels, of which the
accuracy is debatable (vide supra). Moreover, the sample time
was in the order of half an hour. Considering the relatively short
biological half-life of irANF and the rapidly putsatile alterations
in diurnal plasma irANF levels observed in healthy subjects
[221], fast changes in plasma irANF levels may have been
missed. On the other hand, Sagnella et at elegantly demon-
strated that small increments in dietary sodium intake over a
period of several days, were accompanied by gradual increases
in plasma irANF [222]. Nonetheless, there certainly remain as
yet unexplained settings in which endogenous irANF levels do
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not correspond with (changes in) urinary sodium excretion
[217].
We can, however, not deny looking at the host of data
summarized in the above paragraphs, and so elegantly phrased
by Blame: (1.) that ANF has the physiological characteristics to
be a mediator of body fluid regulation; (2.) that ANF satisfies
the conditions to be a component of a physiological feedback-
controlled system; (3.) that ANF is part of a highly complex
integrated system and is one of several jointly necessary factors
that must occur simultaneously to effect natriuresis; (4.) that
ANF at physiological relevant plasma concentrations can ele-
vate urinary sodium excretion for long time periods. Although,
the lack of a demonstrable rise in postprandial irANF levels
may be valid, it is at least hazardous to exclude ANF from a
role in sodium/fluid homeostasis only based on this discordant
finding. In this respect, we should have learned from the
experiences with the history of the RAAS. Only when effective
inhibitors of the different components became available we
started to understand its true significance. Preliminary results
with substances that inhibit the breakdown of endogenous ANF
indeed appear to have significant natriuretic properties [137,
223—2251. Further studies also on the effects of ANF-receptor
agonists or antagonists are clearly needed to unravel the regu-
latory significance of ANF in humans.
Therapeutic applications
From the above we may define at least two areas in which a
possible therapeutic application of ANF may be found. Firstly,
it may be useful in the treatment of high blood pressure. This
may not only be based upon the specific vasodilatory and
diuretic effects of ANF, but also on the fact that ANF may be
hypothesized to play a role in the actual cause of high blood
pressure in essential hypertension (vide supra). We have indeed
shown that a "physiological" dose of ANF certainly is capable
of reducing systemic blood pressure over a long period of time
in patients with essential hypertension [138]. In this study we
showed that a continuous five day infusion of synthetic human
ANF (0.2 tg/min), leading to a doubling of plasma irANF
levels, resulted in a gradual fall of both systolic and diastolic
blood pressure by 11 and 10 per cent, respectively (Fig. 2). The
response was observed in all six studied patients, and blood
pressure recovered slowly to control values after cessation of
ANF infusion. This observation is confirmed by the study of
Cusson et al, who showed that a 12-hour low-dose ANF
infusion slowly lowered the blood pressure in essential hyper-
tensive patients, and not in normotensive controls [144]. Sec-
ondly, ANF could serve as a diuretic in disease states that are
accompanied by sodium/volume retention such as congestive
heart failure (CHF), liver cirrhosis, renal failure, and the
nephrotic syndrome, Studies in CHF demonstrated an in-
creased cardiac performance after bolus injections of ANF
[202, 204]. Crozier Ct al however, failed to show beneficial
effects of ANF given each day as a bolus over a period of 14
days [226], which may be due to the bolus administration
protocol. Until now the longest ANF infusion protocol in
congestive heart failure is to our knowledge 24 hours. This
study in patients with CHF showed a clear, although transient,
improvement in different cardiac indices [227]. In patients with
liver cirrhosis one may discern responders and non-responders
as far as natriuresis is concerned (vide supra). The non-
responders show a clear attenuation of the natriuretic response
to ANF. In patients with the nephrotic syndrome ANF ap-
peared to enhance the urinary protein excretion [198]. Chu eta!
suggested the potential use of ANF as a coronary dilator [228].
Thus, a therapeutic potential for raising endogenous irANF
levels might be expected in patients with essential hypertension
and CHF. The therapeutic use in other disease states remains
questionable.
What has hampered further therapeutic developments was
the fact that the formulation of ANF was such that it could only
be given intravenously. Attempts to alter the administration
route such as intranasal aerosol application have not been
successful, since this did not result in demonstrable absorption
[229]. More promising are the ongoing efforts to design inhibi-
tors of the breakdown of endogenous ANF (atriopeptidase
inhibitors). Preliminary results with these drugs in animal and
human studies look promising [137, 223—225]. The disadvantage
of these atriopeptidase inhibitors is that their action theoreti-
cally depends on the endogenous production (rate) of ANF.
Thus, with even more interest we will welcome the ANF
receptor (ant)agonist [109] not only as a potential drug for
patients with essential hypertension or CHF, but also to further
unravel the function of ANF in normal and disease states.
Summary
The first human studies using relatively high-doses of ANF
revealed similar effects as observed in the preceeding animal
reports, including effects on systemic vasculature (blood pres-
sure fall, decrease in intravascular volume), renal vasculature
(rise in GFR, fall in renal blood flow), renal electrolyte excre-
tion (rises in many electrolytes), and changes in release of a
number of different hormones, Whether all these changes are
the result of direct ANF effects or secondary to a (single)
primary event of the hormone remains to be determined.
Certainly, it has been proven that more physiological doses of
ANF fail to induce short-term changes in many of these
parameters leaving only a rise in hematocrit, natriuresis and an
inhibition of the RAAS as important detectable ANF effects in
humans. This leads us to hypothesize that ANF is a "natri-
uretic" hormone with physiological significance. The primary
function in humans is to regulate sodium homeostasis in re-
sponse to changes in intravascular volume (cardiac atrial
stretch). Induction of excess renal sodium excretion and extra-
cellular volume shift appear to be the effector mechanisms. The
exact mechanism of the natriuresis in humans still needs to be
resolved. It appears however, that possibly a small rise in GFR,
a reduction in proximal and distal tubular sodium reabsorption,
as well as an ensuing niedullary washout, are of importance.
The pathophysiological role of ANF in human disease is un-
clear. One may find elevated plasma irANF levels and/or
decreased responses to exogenous ANF in some disease states.
Whether these findings are secondary to the disease state rather
than the cause of the disease remains to be resolved. Therapeu-
tic applications for ANF, or drugs that intervene in its produc-
tion or receptor-binding, seem to be multiple. Most important
could be the antihypertensive effect, although areas such as
congestive heart failure, renal failure, liver cirrhosis and the
nephrotic syndrome cannot be excluded.
Although the data that have been gathered to date allowed us
to draw some careful conclusions as to the (patho)physiological
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role of ANF, the exact place of ANF in sodium homeostatic
control must still be better defined. To achieve this, we will
need more carefully designed low-dose ANF infusion, as well
as ANF-breakdown inhibitor studies. Even more promising,
however, is the potential area of studies open to us when
ANF-receptor (ant)agonists become available for human use.
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